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ABSTRACT Transcription from the human immunodefi-
ciency virus type 1 promoter gives rise to short cytoplasmic
transcripts of "=60 nucleotides as well as to longer mRNAs.
These RNAs contain the Tat-responsive region sequence, which
is capable of assuming a stemnloop structure and has been
implicated in the regulation of both transcription and trans-
lation. It has been reported that Tat-responsive region RNA
inhibits translation in vitro through activation of an interferon-
induced protein kinase, the double-stranded-RNA-activated
inhibitor, which phosphorylates eukaryotic initiation factor 2.
We show that the activation property is due to double-stranded
RNA that often contaminates RNA synthesized in vitro using
bacteriophage RNA polymerases. After purification, high con-
centrations of Tat-responsive region RNA inhibit the activation
of double-stranded RNA-activated inhibitor, suggesting that it
may serve to protect human immunodeficiency virus type 1
infection from a cellular defense mechanism.
The human immunodeficiency virus type 1 (HIV-1) produces
three major size classes of translatable RNA during its life
cycle (for reviews, see refs. 1-3). In the early stages of
infection, the RNAs- are multiply spliced and encode regu-
latory proteins, whereas late-stage RNAs are singly spliced
or unspliced and encode structural proteins. One of the
regulatory proteins, the trans-acting protein Tat, greatly
stimulates the expression of HIV-1 products. Tat renders its
effect through a sequence known as the Tat-responsive
region (TAR) located downstream from the transcriptional
initiation site in the 5' long terminal repeat (LTR) (1-3).
Originally mapped between nucleotides -17 and +83, rela-
tive to the transcriptional start at +1, the essential region of
the TAR element extends between nucleotides + 19 and +42.
A transcript of the TAR sequence is present in the 5'
untranslated region of all classes of HIV-1 mRNA. Tran-
scription from the HIV-1 promoter also gives rise to a class
of short promoter-proximal RNAs through a process that is
regulated by Tat (4-7). These transcripts also contain the
TAR sequence: they are =60 nucleotides long, nonpolyade-
nylylated, and accumulate in the cytoplasmic fraction, but
their significance is not known. The TAR RNA sequence is
predicted to form a stable stem-loop structure comprising
nucleotides +1 to +59 (8, 9). In addition, a second stem-loop
structure, extending from +60 to +104, is predicted for
longer HIV RNAs (9). Empirical evidence for the existence
of this secondary structure comes from ribonuclease-
sensitivity probing (9), and additional support can be drawn
from mutagenic studies (6, 10-12) and comparisons with
HIV-2 (10, 13). The stem-loop structure encompassing the
TAR region plays an important role in Tat-mediated tran-
scriptional activation (6, 9-12, 14) and interacts directly with
the Tat protein (15, 16).
In contrast to this positive transcriptional role, it has been
reported that the TAR RNA structure exerts a negative effect
on mRNA translation in cis and in trans. Secondary structure
in the 5' untranslated region ofmRNA lowers its translational
efficiency in cis (17). Consequently, mRNA with a TAR
leader sequence is translated poorly compared to that without
a leader or with a leader in which the stem is interrupted (18).
The stem structure ofTAR RNA is also reported to inhibit the
initiation of translation in vitro by activating the double-
stranded-RNA (dsRNA)-activated inhibitor of protein syn-
thesis (DAI) (19, 20). DAI (also known as dsI and p68) is an
interferon-induced protein kinase that is normally found in an
inactive latent form. When activated by dsRNA, it phospho-
rylates eukaryotic initiation factor 2 (elF-2), which then
sequesters an essential second initiation factor (elF-2B or
GEF) and blocks protein synthesis in trans (for reviews, see
refs. 21-23).
Results presented here show that the DAI activation prop-
erty associated with TAR RNA transcribed in vitro is not due
to TAR RNA per se. After rigorous purification of the
synthetic RNA, its ability to activate DAI was lost. On the
contrary, at high concentrations, purified TAR RNA pre-
vents the activation of DAI by ds'RNA. By analogy with
adenovirus virus-associated (VA) RNA, which also blocks
DAI activation and renders adenovirus infection resistant to
interferon (24, 25), TAR RNA may serve to neutralize a
cellular defense mechanism during HIV-1 infection.
MATERIALS AND METHODS
Plasmid Construction. The plasmid pEM-7 was constructed
by E. Mathews and M. Laspia-(Cold Spring Harbor Labo-
ratory, Cold Spring Harbor, NY) to direct initiation by T7
RNA polymerase at nucleotide +1 of HIV-1. Nucleotides
+21 to +82 of the HIV-1 LTR were excised from pU3R-III
(26) and inserted between the HincII and HindIII sites of
pUC118 with a Bgl TT linker at the former site. The Bgl
TT-BamHT fragment of this construct was replaced by the
equivalent fragment from pET-7 containing the 410 promoter
of bacteriophage T7 (27). Finally, complementary synthetic
oligonucleotides corresponding to nucleotides +3 to +20 of
the HIV-1 LTR were annealed and ligated between the Stu I
site of the T7 promoter and the Bgl IT site.
TAR RNA Preparation. pEM-7 was linearized at nucleotide
+82 by digestion with HindITI and transcribed using T7 RNA
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polymerase purified as described (28). Transcription and
RNA purification followed procedures devised in this labo-
ratory (29). Briefly, TAR RNA labeled with [a-32P]GTP was
purified through three steps. It was first subjected to elec-
trophoresis in a sequencing-type 7 M urea/8% polyacrylam-
ide gel and the major radioactive band was eluted. The RNA
was extracted with phenol/chloroform and precipitated with
ethanol. This stage 1 TAR RNA was then resolved in a
nondenaturing 8% polyacrylamide gel. After phenol/chloro-
form extraction and ethanol precipitation, the RNA recov-
ered from this second gel (stage 2TARRNA) was loaded onto
a cellulose CF-11 column (30) in 35% (vol/vol) ethanol/STE
buffer (10 mM Tris HCl, pH 8.0/100mM NaCl/l mM EDTA)
and eluted with 15 or 22% ethanol/STE. RNA was precip-
itated from peak fractions and dissolved in TE buffer (10 mM
Tris HCl, pH 7.4/1 mM EDTA), giving stage 3 TAR RNA.
RNA concentrations were determined spectrophotometri-
cally.
Other RNAs. Anti-TAR RNA was transcribed by SP6 RNA
polymerase from plasmid pGEM23 (7) digested with Rsa I.
SP6 polymerase reactions were as specified by the manufac-
turer (Promega) and the RNA was purified as described
above. The resultant RNA was complementary to TAR RNA
with 4 extra nucleotides (complementary to nucleotides -1 to
-4 of the HIV-1 LTR) at the 3' end and 5 nucleotides from
polylinker sequences at the 5' end. VA RNA, was synthe-
sized in vitro and purified as described (29). Short dsRNAs
were produced by symmetrical transcription of a polylinker
(ref. 23; L. Manche and M.B.M., unpublished results).
Reovirus dsRNA was kindly provided by A. Shatkin (Waks-
man Institute, Rutgers University, New Brunswick, NJ).
Kinase Assays. DAI was purified from the ribosome salt-
wash fraction of interferon-treated 293 cells through the
hydroxylapatite stage (23). Kinase assays were conducted in
the presence of [y-32P]ATP and the RNAs under test. Prod-
ucts were analyzed by electrophoresis in SDS/polyacryl-
amide gels and autoradiography (23).
Ribonuclease Digestion. RNA was incubated with RNase
Ti (Calbiochem) for 30 min at 37°C in TE buffer at an
enzyme/substrate ratio of 1:10 (wt/wt). After incubation for
an additional 15 min with 0.5% SDS/proteinase K (Boeh-
ringer Mannheim; 0.2 mg/ml), RNA was recovered by phe-
nol/chloroform extraction and ethanol precipitation in the
presence of glycogen (20 ,ug/ml) as carrier. The precipitate
was dissolved in TE buffer and a fraction was analyzed in a
7M urea/8% polyacrylamide gel to verify complete digestion
of TAR RNA. RNA was digested with RNase III (phospho-
cellulose fraction; ref. 31) in a similar fashion except that 200
ng of RNA was incubated with 6 units of RNase III in a
digestion buffer [20mM Tris HCl, pH 7.6/100 mM NH4Cl/10
mM magnesium acetate (32)].
RESULTS
DAI Activation by Partially Purified TAR RNA. TAR RNA,
corresponding to nucleotides + 1 to +82 of the HIV-1 LTR,
was synthesized in vitro using T7 RNA polymerase and was
initially purified by electrophoresis through a denaturing
polyacrylamide gel (stage 1 RNA). In agreement with previ-
ous results (19,20), the partially purified RNA activated DAI,
as evidenced by autophosphorylation of the enzyme itself
(Fig. la) and phosphorylation of its substrate, eIF-2 (Fig. 2a,
lane 3). Activation required much higher concentrations of
TARRNA than ofdsRNA prepared from reovirus (-40 times
higher; Fig. la). Furthermore, unlike authentic dsRNA,
which activates at low concentrations but fails to activate at
high concentration (1 ,ug/ml) (for review, see ref. 33), the
partially purified TAR RNA continued to activate DAI at the
highest concentrations tested (Fig. la). These observations
could imply mechanistic differences between TAR RNA and
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FIG. 1. DAI activation by crude (stage 1) TAR RNA. (a) DAI
activation assays contained no RNA (lane 1), reovirus dsRNA (10
ng/ml; lane 2), or the indicated concentrations of stage 1 TAR RNA
(lanes 3-9). (b) RNase sensitivity of the activation property of stage
1 TAR RNA. Reactions contained TAR RNA (200 ng/ml) treated
with RNase III (lane 1) or RNase T1 (lane 3) or untreated (lane 2).
Control assays contained no RNA (lane 4) or reovirus dsRNA (10
ng/ml; lane 5). The position of 32P-labeled DAI is marked.
longer dsRNAs in their interactions with DAI but could also
reflect the presence of low levels of dsRNA contaminants in
the stage 1 TAR RNA preparation.
To address the second possibility, we examined the sen-
sitivity of the activation property toward the nucleases
RNase Ti and RNase ITI. TAR RNA, being an imperfect
stem-loop structure, is digested by the single-stranded RNA-
specific enzyme RNase Ti (ref. 9 and see Fig. 4). RNase III,
on the other hand, digests perfectly duplexed dsRNA >20
base pairs (bp) long (32) and is unable to act upon imperfectly
paired duplexes unless they have a specific stem-bulge
structure, as in some prokaryotic RNA processing sites (34).
TAR RNA forms an imperfect 24-bp duplex (9) and is
insensitive to RNase III digestion (Fig. 4, lanes 3 and 4). Fig.
lb shows that the capability of partially purified TAR RNA
to activate DAI was unaffected by RNase T1 digestion but
was ablated by incubation with RNase III. The reverse would
be expected if TAR RNA itself were responsible for activa-
tion of DAI. Similar results were obtained with TAR-CAT
fusion RNAs (19) transcribed by SP6 RNA polymerase (data
not shown), suggesting that the activation ofDAI by partially
purified RNA is probably due to a dsRNA contaminant rather
than TAR RNA itself.
TAR RNA Loses the Ability to Activate DAI on Purification.
The partially purified TAR RNA, fractionated in a denaturing
gel (stage 1 RNA), was further purified by electrophoresis
through a nondenaturing gel (stage 2 RNA) and then by
chromatography over a cellulose column under conditions
designed to separate single-stranded RNA and dsRNA (stage
3 RNA). The kinase assays in Fig. 2a show that both DAI
autophosphorylation and eTF-2 phosphorylation were dras-
tically reduced when TAR RNA was purified to stage 2 or
stage 3. Little or no activity was observed when the fully
purified (stage 3) TAR RNA was tested over a wide range of
concentrations (Fig. 2b). In case the RNA remained partially
denatured after the purification, we heated samples of stage
3 RNA to 95°C and allowed them to cool slowly in the
presence of potassium chloride, magnesium chloride, or both
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FIG. 2. DAI activation capacity of purified TAR RNA. (a) The
kinase activation reactions contained eIF-2 and TAR RNA (200
ng/ml) at different stages of purification (lanes 3-5). The positions of
DAI, the a subunit of eIF-2, and molecular mass standards are
indicated. Lane 1 contained no RNA and lane 2 contained reovirus
dsRNA. (b) Kinase assays contained increasing concentrations of
purified TAR RNA (stage 3), as indicated. (c) Comparison of
activation capabilities of stage 3 TAR RNA (lanes 7 and 8) and
adenovirus VA RNA, (lanes 9 and 10) with 15-bp dsRNA (lanes 3 and
4) or 34-bp dsRNA (lanes 5 and 6). Control assays contained no RNA
(lane 1) or reovirus dsRNA (10 ng/ml; lane 2).
to allow the native conformation to reform. The treated TAR
RNA samples also failed to activate DAI (data not shown).
These data indicate that the ability to activate DAI is not an
intrinsic property of TAR RNA.
Earlier studies suggested that the minimum length of
dsRNA capable of activating DAI is 50 bp (35), but recent
work indicates that shorter duplexes can activate, albeit to a
lesser degree, provided they are at least 30 bp long (L.
Manche and M.B.M., unpublished results). The experiment
shown in Fig. 2c compares the ability of various short RNA
duplexes to elicit DAI autophosphorylation. A perfect 34-bp
duplex exhibited low but significant activity whereas the
activity of a similar 15-bp duplex was barely detectable. In
keeping with these findings, TAR RNA and adenovirus VA
RNA&, which have no more than 11 bp of continuous duplex
in their stem regions, were also barely active in this assay.
Thus, there is no evidence that a special ability to activate
DAI is conferred upon TAR RNA by its structure or se-
quence.
TAR RNA Can Block DAI Activation. Some RNA species
that fail to activate DAI are nevertheless able to interact with
the enzyme in such a way as to prevent its activation. The
ability to block DAI autophosphorylation and activation is
exhibited by short dsRNAs and by some small highly struc-
tured RNAs such as VA RNA, (24, 25, 33, 35) and possibly
the Epstein-Barr encoded small RNAs (EBERs) of Epstein-
Barr virus (36). To explore the possibility that TAR RNA
functions in this way, various concentrations of reovirus
dsRNA and TAR RNA were incubated with DAI. As shown
in Fig. 3, TAR RNA blocked activation ofDAI by dsRNA in
a concentration-dependent fashion. At higher concentrations
TAR RNA- *
FIG. 3. TAR RNA blocks activation of DAI by dsRNA. DAI
assays were performed in the presence of reovirus dsRNA and stage
3 TAR RNA at the concentrations indicated.
ofdsRNA, more TAR RNA was required to block activation.
To ensure that the inhibition is due to TAR RNA, we
examined the nuclease sensitivity of the inhibitor. Fig. 4
shows that the RNase sensitivity of the inhibitory component
matches that ofTAR RNA: both were eliminated by RNase
T1, but neither was affected by RNase ITT. Thus, the inhibi-
tion is an intrinsic property of TAR RNA.
At very high concentrations (>50 ,ug/ml), RNA can pre-
vent the activation of DAI without any apparent specificity
(ref. 24 and unpublished results). To assess the specificity of
the inhibition by TAR RNA, the complementary sequence
(anti-TAR RNA, nucleotides +82 to -4) was synthesized in
vitro and purified through the three-step purification de-
scribed above. Anti-TAR RNA did not inhibit DAI activation
except at 100 ,ug/ml (compare Fig. 5, lanes 3-5, with lanes
6-8). We conclude that TAR RNA is able to serve as a
specific inhibitor of DAI activation.
DISCUSSION
The protein kinase DAI is one component of the cellular
anti-viral defenses (37, 38). Its synthesis is elevated by
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FIG. 4. RNase sensitivity ofTAR RNA and DAI activation. DAI
assays were performed in the presence of reovirus dsRNA at 10
ng/ml alone (lanes 1 and 2) or with stage 3 TAR RNA at 25 ,ug/ml
(lanes 5 and 7) or 50 Ag/ml (lanes 3, 4, 6, and 8). The RNAs were
treated with RNase III or RNase T1 as indicated.
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FIG. 5. Effect of anti-TAR RNA on DAI activation. DAI assays
were performed with reovirus dsRNA, stage 3 TAR RNA, and stage
3 anti-TAR RNA, at the concentrations indicated. -, Reovirus
dsRNA absent; +, reovirus dsRNA present.
interferon, and its activity is unmasked by dsRNA, which is
a frequent concomitant of viral infection. Activation of the
enzyme blocks protein synthesis by phosphorylation of an
initiation factor, eIF-2, which is one of its few known
substrates. DAI is activated by very low concentrations of
dsRNA (33) and uninfected cells may possess detoxification
mechanisms to dispose ofdsRNA that accumulates as a result
of normal metabolism (39, 40). Presumably, these safety
mechanisms are saturated or otherwise incapacitated during
viral infection, allowing dsRNA to accumulate and trigger the
activation of DAI and other dsRNA-dependent enzymes. For
their part, several viruses have acquired the means to evade
this anti-viral defense (41). These countermeasures involve
viral proteins, as in influenza, polio-, reo-, and vaccinia
viruses, and viral RNAs, as in adenovirus and perhaps
Epstein-Barr virus. The work presented here raises the
possibility that the HIV-1 TAR RNA may also play such a
role.
Present at the 5' end of all HIV mRNAs and in a free
cytoplasmic form, the TAR sequence adopts a stem-loop
structure that can interact with DAI. Being <30 bp long, the
TAR RNA duplex fails to activate DAI as longer perfect
duplexes do, but at high concentration it prevents DAI
activation. In this respect it resembles adenovirus VA RNA&,
a 160-nucleotide transcript synthesized by RNA polymerase
III (24, 25, 33). Both of these species of small stable cyto-
plasmic viral RNA are highly structured even though they
behave as predominantly single-stranded molecules with
regard to their chromatographic properties and nuclease
sensitivity (9, 42).
A large body of genetic and biochemical evidence demon-
strates that the role of VA RNA is to preserve protein
synthesis during adenovirus infection from the consequences
of DAI activation by dsRNA made in the late phase of
infection (21, 24, 25, 43). While VA RNA is abundant in
adenovirus-infected cells, it is not known whether the short
TAR transcripts accumulate sufficiently in HIV-1-infected
cells to block DAI activation: more data from cells of various
types and in various stages of infection will be needed to
settle this issue. However, it may be significant that the TAR
sequence is also carried by HIV mRNAs, in an ideal position
to spare them from the inhibitory effect of DAI activation on
polypeptide chain initiation. DAI is bound to ribosomes, and
the idea that its activity can be controlled at a local level has
precedents in vivo and in vitro (44, 45). Thus, it has been
proposed that VA RNA ensures the preferential translation of
mRNAs with which it is specifically associated (45-47).
Similarly, by keeping DAI inactive, the TAR sequence at the
5' end of HIV mRNAs may allow them to be translated
preferentially. This may be important in the presence of
interferon or during the early stages of infection when the
level of full-length HIV transcripts in the cytoplasm is low.
Earlier studies concluded that TAR-containing RNA, tran-
scribed in vitro and used after limited purification, is an
activator of DAI (19, 20). Our work leads to the opposite
conclusion and suggests that the explanation for the con-
trasting results lies in the sensitivity of DAI to very low
concentrations of dsRNA, coupled with the ability of bacte-
riophage RNA polymerases to produce dsRNA in small
quantities (29, 48, 49). Evidently under some conditions, T7
RNA polymerase can also use highly structured RNAs as a
template, generating dsRNA (50). As shown here and else-
where (29), purification over a denaturing gel may not ade-
quately remove dsRNA contamination. When this was ac-
complished by further steps of purification, the activation
capacity of the TAR RNA was lost and its ability to block
activation was revealed.
It is now widely accepted that Tat regulates transcription
from the HIV LTR, but its role in translational control
remains controversial. Several studies have concluded that
Tat and TAR cooperate to regulate translation, either as well
as or instead of transcription, whereas other studies failed to
discern an effect at the translational level (1, 3). The findings
described here may provide a basis for reconciling these
discrepancies. Basal levels of DAI vary greatly among cell
types and possibly as a result of growth conditions (38).
Accordingly, the requirement for VA RNA, during adenovi-
rus infection is reduced or eliminated when the DAI concen-
tration is low (45, 51). The requirement is also influenced by
a number of other factors, including eIF-2 mutations (52, 53),
trans-acting proteins (54), and mechanisms that are presently
unknown (55). On the other hand, in transfection experi-
ments, factors that lead to dsRNA accumulation increase the
requirement for VA RNA (47, 56). If TAR RNA acts like VA
RNA to block the activation of DAI, the expression of HIV
transcripts at a high level (for example, because of the
presence of Tat) might increase protein synthesis in some cell
lines or experimental conditions but not in others. This may
account, at least in part, for the variability reported in the
literature.
Finally, in addition to immunological abnormalities, AIDS
is accompanied by a suppression of the interferon-mediated
defense system. For example, interferon-a and
-y production
declines and exogenously administered interferon-a fails to
augment (2'-5')oligoadenylate synthetase levels (57). More-
over, a decrease in DAI levels has been observed in HIV-
infected cells (58). Since HIV-1 replication is sensitive to
interferon, the inhibition of DAI activation by TAR RNA
may be seen as a further aspect of the disarming of host
defenses by the virus.
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